1123TiPA randomized phase II study of cisplatin plus radiotherapy versus durvalumab plus radiotherapy followed by adjuvant durvalumab versus durvalumab plus radiotherapy followed by adjuvant tremelimumab and durvalumab in intermediate risk, HPV-positive, locoregionally advanced oropharyngeal squamous cell cancer (LA-OSCC) (Canadian Cancer Trials Group HN.9)

A Spreafico, K Sultanem,B Chen,S V Bratman, J Ringash, A V Louie, A McNiven, K Whelan,J Hilton,J Yoo,J-P Machiels, L. Licitra,S Oosting, J Waldron,Lillian L. Siu,W R Parulekar

Annals of Oncology(2018)

引用 3|浏览154
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要